We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    regeneron | Cat Allergy
Previous Study | Return to List | Next Study

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04981717
Recruitment Status : Active, not recruiting
First Posted : July 29, 2021
Last Update Posted : March 24, 2023
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.

The Secondary Objectives are:

  • To assess the reduction of allergic symptoms and use of allergy rescue medications after treatment with REGN1908-1909 versus placebo, as measured by the individual components of the CSMS
  • To assess health-related quality of life (HRQoL) as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ[S])
  • To determine the efficacy of REGN1908-1909, as compared to placebo, to inhibit a wheal-and-flare response to a skin prick test with cat allergen
  • To assess the durability of effect in allergic rhinitis and conjunctivitis symptom and medication scores after multiple doses of REGN1908-1909 compared to placebo given every 12 weeks (Q12W)
  • To determine the efficacy following multiple doses of REGN1908-1909 compared to placebo at inhibiting a wheal-and-flare response to a skin prick test with cat allergen
  • To estimate the effect of REGN1908-1909 on lung function, as compared to placebo, in patients with asthma
  • To determine the efficacy of REGN1908-1909 as compared to placebo to reduce asthma symptoms in patients with asthma
  • To assess whether there is a difference in asthma rescue medication use in patients with asthma who are treated with REGN1908-1909 compared to placebo
  • To assess whether there is a difference in nighttime awakenings in patients with asthma treated with REGN1908-1909 compared to placebo
  • To evaluate the short-term and long-term safety and tolerability of REGN1908-1909, including the incidence of hypersensitivity reactions, local injection site reactions, and asthma exacerbations
  • To determine systemic exposure of total (free and antigen-bound) antibodies as measured by concentration of REGN1908 and REGN1909
  • To assess the immunogenicity of REGN1908 and REGN1909

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Due to Cat Allergy Drug: REGN1908-1909 Drug: Matching Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 446 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home
Actual Study Start Date : July 30, 2021
Actual Primary Completion Date : January 4, 2023
Estimated Study Completion Date : April 24, 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: REGN1908-1909
Randomized 1:1
 Drug: REGN1908-1909
Subcutaneous (SC) for a total of 5 administrations
Placebo Comparator: Placebo
Randomized 1:1
 Drug: Matching Placebo
SC for a total of 5 administrations


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Daily combined symptom and medication score (CSMS) averaged over last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo. [ Time Frame: Weeks 48 to 60 ]
    CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).


Secondary Outcome Measures :
  1. Daily total nasal symptom score (TNSS) averaged over the last 12 weeks of treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
    Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.

  2. Percent change from pre-treatment baseline in average CSMS over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  3. Percent change from pre-treatment baseline in average TNSS over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  4. Daily total symptom score (TSS) averaged over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
    TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)

  5. Percent change from pre-treatment baseline in average TSS over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  6. Percent change from baseline to the end of treatment in cat skin prick test (SPT) mean wheal diameter in patients who receive REGN1908-1909 versus placebo [ Time Frame: Week 60 ]
  7. Daily CSMS averaged over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  8. Daily TNSS averaged over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  9. Percent change from pre-treatment baseline in average CSMS over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  10. Percent change from pre-treatment baseline in average TNSS over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  11. Percent change from pre-treatment baseline in average TSS over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  12. Daily TSS score averaged over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  13. Percent change from pre-treatment baseline in average TOSS, over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
    Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)

  14. Daily TOSS averaged over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  15. Percent change from pre-treatment baseline in average TOSS over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  16. Percent change in forced expiratory volume (FEV)1 in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 12 ]
  17. Percent change in FEV1 in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 60 ]
  18. Percent change in cat SPT mean wheal diameter in patients who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 12 ]
  19. Change in FEV1 in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 12 ]
  20. Change in FEV1 in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 60 ]
  21. Change in Rhinoconjunctivitis Quality of Life Questionnaire for Ages 12+ (RQLQ(S)+12) in patients who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 60 ]
    The RQLQ has 25 questions in 6 domains (nose symptoms, eye symptoms, practical problems, activity limitation, non-hay fever symptoms and emotional function). Patients recall how they have been during the previous week and respond to each question on a 7-point scale. The overall RQLQ score is the mean of all 25 responses and the individual domain scores are the means of the items in those domains.

  22. Daily medication score (DMS) averaged over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
    The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication. The scale is 0 (minimum) to 20 (maximum)

  23. DMS averaged over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  24. Percent change from pre-treatment baseline in average DMS averaged over the last 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  25. Percent change in cat SPT mean wheal diameter in patients who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 72 ]
  26. Asthma daily symptom (ADS) score, averaged over the initial 12 weeks of the treatment period using Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
    The total daily asthma symptom score is a patient-reported outcome concerning the occurrence of asthma symptoms and their effect on a patient's daily activities and sleep. It is composed of two parts: daytime (five items) and nighttime (four items), both scored ordinally. Higher scores indicate more severe symptoms.

  27. ADS score averaged over the last 12 weeks of the treatment period using ADSD and the ANSD in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  28. Daily TOSS averaged over the initial 12 weeks of the treatment period in patients who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  29. Change from baseline to week 60 in Asthma Control Questionnaire 5 Question Version (ACQ-5) in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Baseline to week 60 ]
    The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control.

  30. Daily number of nighttime awakenings averaged over the initial 12 weeks of the treatment period in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 0 to 12 ]
  31. Daily number of nighttime awakenings averaged over the last 12 weeks of the treatment period in patients with asthma who receive REGN1908-1909 versus placebo [ Time Frame: Weeks 48 to 60 ]
  32. Incidence of treatment-emergent adverse events (TEAEs) throughout the study [ Time Frame: Weeks 0 to 72 ]
  33. Incidence of adverse event of special interests (AESIs) throughout the study [ Time Frame: Weeks 0 to 72 ]
  34. Incidence of serious TEAEs throughout the study [ Time Frame: Weeks 0 to 72 ]
  35. Total REGN1908 concentration in serum over the study duration [ Time Frame: Weeks 0 to 72 ]
  36. Total REGN1909 concentration in serum over the study duration [ Time Frame: Weeks 0 to 72 ]
  37. Incidence of treatment-emergent anti-drug antibodies (ADAs) to REGN1908 throughout the study [ Time Frame: Weeks 0 to 72 ]
  38. Incidence of treatment-emergent ADAs to REGN1909 throughout the study [ Time Frame: Weeks 0 to 72 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Generally healthy males and females who are 12 years and older at the time of screening.
  2. Weight must be ≥40 kg at the time of screening

  3. Documented or patient reported history (for at least 2 years) of symptomatic cat allergen-triggered allergic rhinitis with or without conjunctivitis and with or without asthma as defined by all of the following criteria:

    1. Positive skin prick test (SPT) with cat hair extract (mean wheal diameter at least 5 mm greater than a negative control) at screening
    2. Positive allergen-specific IgE (sIgE) tests for cat and Fel d 1 (both ≥0.7 kUa/L at screening)
    3. Documented or patient reported history of nasal and/or ocular symptoms upon cat exposure
    4. Symptomatic despite the use of medications to treat their nasal and/or ocular symptoms
  4. At least 1 generally healthy cat (that is unlikely to die during the study) living in the home resulting in regular exposure
  5. A daily total rhinitis/conjunctivitis symptom score (total symptom score [TSS]) of at least 8 of 18 during at least 8 days of the 15-day baseline assessment period and use of standard, therapeutic doses of pharmacotherapy for the treatment of allergic rhinoconjunctivitis on at least 8 days of the 15-day baseline assessment period.

Key Exclusion Criteria:

  1. History of significant multiple and/or severe allergies, as assessed by the investigator, that would potentially interfere with the assessments during the baseline and 12-week efficacy assessment periods or confound results, per investigator discretion, including significant rhinitis or sinusitis due to daily contact with other allergens causing symptoms that are expected to coincide with the baseline period or any of the efficacy assessment periods
  2. Received REGN1908-1909 in a prior REGN1908-1909 clinical trial (receipt of placebo in a previous trial is allowed)
  3. Active lung disease other than asthma
  4. FEV1 less than 70% of predicted at screening or randomization
  5. Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to screening
  6. Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections within 4 weeks prior to screening. Patients may be re-evaluated after resolution of symptoms and specified time duration

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04981717


Locations
Show Show 92 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04981717    
Other Study ID Numbers: R1908-1909-ALG-2102
2021-002089-42 ( EudraCT Number )
First Posted: July 29, 2021    Key Record Dates
Last Update Posted: March 24, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Cat allergy induced allergic rhinitis
Allergic conjunctivitis
Asthma
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Rhinitis
Rhinitis, Allergic
Immune System Diseases
 Respiratory Tract Infections
Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases